Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory Diseases

Companies to create novel antibody therapeutics to treat fibrosis across a broad range of indications Ono to leverage Mediar's expertise in antibody discovery and harness its deep understanding of myofibroblast biology to develop a new class of multimodal therapies BOSTON, Aug. 6, 2026...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.